
Precigen (PGEN) Stock Forecast & Price Target
Precigen (PGEN) Analyst Ratings
Bulls say
Precigen is a commercial-stage biopharmaceutical company with a positive outlook due to its strong pipeline of precision medicines, including its AdenoVerse and UltraCAR-T platforms. The company's recent updates on its PRGN-2009 oncology asset and the early success of its Papzimeos launch have boosted investor confidence. With promising clinical data, market exclusivity, and potential label expansions, Precigen is poised for growth and has a current price target of $14 per share.
Bears say
Precigen is currently maintaining a Buy rating on PGEN with a 12-month price target of $14.00 per diluted share, derived from a risk-adjusted net present value analysis of projected future revenues from its lead product Papzimeos. However, this outlook is reliant on successful clinical, regulatory, commercial, partnership, financial, and intellectual property factors. Expansion opportunities for Papzimeos into pediatrics and redosing could provide incremental updates and investors expect positive Phase 2 data for PRGN-2009 by year-end, potentially extending the company's investment thesis in HPV-driven oncology markets.
This aggregate rating is based on analysts' research of Precigen and is not a guaranteed prediction by Public.com or investment advice.
Precigen (PGEN) Analyst Forecast & Price Prediction
Start investing in Precigen (PGEN)
Order type
Buy in
Order amount
Est. shares
0 shares